500 Shares in Illumina, Inc. (NASDAQ:ILMN) Bought by nVerses Capital LLC

nVerses Capital LLC bought a new position in Illumina, Inc. (NASDAQ:ILMN) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 500 shares of the life sciences company’s stock, valued at approximately $65,000.

A number of other large investors have also recently added to or reduced their stakes in the company. Trivant Custom Portfolio Group LLC grew its stake in shares of Illumina by 166.7% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock worth $27,000 after acquiring an additional 125 shares in the last quarter. Industrial Alliance Investment Management Inc. bought a new position in Illumina in the second quarter valued at $34,000. Versant Capital Management Inc increased its stake in Illumina by 292.9% in the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after buying an additional 246 shares during the last quarter. Massmutual Trust Co. FSB ADV lifted its position in Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after buying an additional 168 shares in the last quarter. Finally, Itau Unibanco Holding S.A. acquired a new position in shares of Illumina during the 2nd quarter worth about $61,000. Institutional investors own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Citigroup upped their target price on Illumina from $140.00 to $155.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. TD Cowen upgraded Illumina from a “hold” rating to a “buy” rating and upped their price objective for the stock from $126.00 to $144.00 in a research note on Wednesday, August 14th. Barclays raised their target price on shares of Illumina from $125.00 to $135.00 and gave the company an “equal weight” rating in a research note on Tuesday, October 15th. Leerink Partners increased their price target on shares of Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Finally, Stephens restated an “overweight” rating and set a $170.00 price objective on shares of Illumina in a research note on Wednesday, July 10th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $154.33.

Illumina Price Performance

Shares of Illumina stock opened at $145.21 on Tuesday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 1.04. The stock has a market capitalization of $23.13 billion, a price-to-earnings ratio of -17.82 and a beta of 1.15. Illumina, Inc. has a twelve month low of $89.00 and a twelve month high of $151.40. The company has a 50-day simple moving average of $133.15 and a two-hundred day simple moving average of $121.24.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.24. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The firm’s quarterly revenue was down 5.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.32 earnings per share. Analysts forecast that Illumina, Inc. will post 3.63 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.